Patents Assigned to Taiho Pharmaceitucal Co., Ltd.
  • METHOD FOR PREDICTING THERAPEUTIC EFFICACY OF PI3K/AKT/mTOR INHIBITOR ON BASIS OF PHLDA1 OR PIK3C2B EXPRESSION
    Publication number: 20160102366
    Abstract: An object of the present invention is to provide a chemotherapy using a PI3K/AKT/mTOR inhibitor that produces an excellent antitumor effect on a cancer patient. The present invention provides a method for predicting the therapeutic efficacy of the chemotherapy using the antitumor agent comprising a PI3K/AKT/mTOR inhibitor on a cancer patient on the basis of the expression level of PHLDA1 and/or PIK3C2B in a biological sample containing tumor cells isolated from the cancer patient.
    Type: Application
    Filed: June 19, 2014
    Publication date: April 14, 2016
    Applicant: Taiho Pharmaceitucal Co., Ltd.
    Inventors: Tetsuya ABE, Hiraku ITAKDANI